Lp(a): The Complete Guide to Lipoprotein(a) and Your Cardiovascular Risk

You can do everything right — normal cholesterol, good blood pressure, an active life — and still carry a meaningful, invisible cardiovascular risk written into your genes. Lipoprotein(a), written Lp(a), is that risk for roughly one in five adults. It is inherited, largely fixed for life, and almost never included on a standard lipid panel. The good news: it takes a single test, once, to know where you stand.

What Is Lp(a)?

Lipoprotein(a) is a particle in your blood that looks a lot like LDL — the "bad cholesterol" particle — with one important addition. Each Lp(a) particle is built on an ApoB core (the same protein that defines LDL and other atherogenic particles) with an extra protein called apolipoprotein(a), or apo(a), wrapped around it. That apo(a) tail is what makes Lp(a) distinct — and what makes it dangerous in ways ordinary LDL is not.

Why it's different from LDL cholesterol

Two features set Lp(a) apart. First, it is inherited and lifelong: your level is determined largely by the gene you're born with (the LPA gene) and changes very little across your life, regardless of diet or lifestyle. Second, it appears to do damage through more than one pathway — contributing not only to the cholesterol build-up of atherosclerosis, but also to inflammation, clot formation, and the calcification of the aortic valve. For a side-by-side look at how Lp(a) differs from a standard cholesterol reading, see Lp(a) vs LDL.

Why Lp(a) Matters

Lp(a) is not just associated with cardiovascular disease — the evidence points to it being a causal driver. That distinction matters: a causal factor is one that actually contributes to disease, not merely a bystander that travels alongside it.

High Lp(a) is linked to a higher lifetime risk of:

• Heart attack and coronary artery disease — the classic atherosclerotic pathway.
• Ischemic stroke — particularly relevant at younger ages.
• Aortic valve stenosis — a progressive narrowing of the aortic valve, a link fairly unique to Lp(a) among lipid markers.

Because the risk is present from birth and accumulates over decades, high Lp(a) is one reason some people develop cardiovascular disease unexpectedly early, or despite otherwise excellent numbers.

What the Evidence Shows

The case for Lp(a) as a causal risk factor rests on two strong pillars of evidence. Large genetic (Mendelian randomization) studies — which use inherited variation to separate cause from coincidence — consistently link genetically higher Lp(a) to higher cardiovascular risk. And large population studies show the same relationship holds across hundreds of thousands of people.

On the strength of this evidence, the European Atherosclerosis Society (EAS) 2022 consensus statement recommends that Lp(a) be measured at least once in the lifetime of every adult, to identify those with very high inherited risk. This "once in a lifetime" principle follows directly from the biology: because your level is largely fixed, one accurate measurement tells you most of what you need to know.

What Counts as a High Lp(a) Level?

Lp(a) is best reported in nmol/L (nanomoles per litre), which counts particles directly. You may also see it in mg/dL (a measure of mass). The two units do not convert by a single fixed factor — the relationship depends on the particle and the laboratory assay — so it's best to track your result in nmol/L where possible and compare like with like over time.

As with ApoB, the useful distinction is between a lab's population range and a risk-based threshold. The values below are widely-referenced reference points, not diagnostic cut-offs — your physician interprets them alongside your full risk picture.

Reference points only; exact thresholds vary by guideline, assay, and population, and interpretation belongs to your physician. Track results in nmol/L and compare like with like.

Who Should Be Tested — and When

The EAS position is straightforward: every adult should have Lp(a) measured at least once. Because the result is largely stable for life, that single test is usually enough to know whether inherited Lp(a) is part of your risk picture. Testing matters even more if any of the following apply:

The test itself is a simple blood draw and does not require fasting. If your first-ever result is high, it rarely needs repeating for the number's sake — but it becomes an important, permanent part of how your overall risk is understood.

What You Can Do About High Lp(a)

Here is the honest state of play, and the single most important thing to understand about managing Lp(a):

The strategy: lower everything else, aggressively

If Lp(a) is a fixed source of risk you can't yet lower directly, the logical response is to reduce every other source of risk as much as possible — so your total risk is minimised. In practice, that means working with your physician to:

• Optimise your atherogenic particle burden — driving ApoB and LDL-C to the targets appropriate for your risk category. Every unit of that burden you remove counts for more when Lp(a) is high. Start with the ApoB guide.
• Address blood pressure, glucose, and smoking — the other major, and modifiable, contributors to cardiovascular risk.
• Screen your family — see below.

A note on statins, niacin, and supplements

Two common points of confusion are worth clearing up. Statins may raise Lp(a) slightly, but this is not a reason to avoid them — they substantially lower ApoB and overall cardiovascular risk, which is the priority when Lp(a) is high. Niacin can modestly lower Lp(a) but has not been shown to improve cardiovascular outcomes, so it is not recommended for this purpose. No dietary supplement has good evidence for lowering Lp(a) or the risk it carries. As always, any medication decision belongs to you and your physician.

What's coming

Several investigational therapies designed specifically to lower Lp(a) — including pelacarsen, olpasiran, and others — are in advanced clinical trials. These are not yet approved, and it is not yet known whether lowering Lp(a) with them reduces cardiovascular events; the outcome trials are still underway. For where this science stands today, see Pelacarsen and Olpasiran.

Family and Inheritance

Because Lp(a) is passed down genetically, a high result in one person is a signal to look at the wider family. On average, a first-degree relative — a parent, sibling, or child — has a meaningfully higher chance of also carrying an elevated level. If your Lp(a) is high, it's worth letting close relatives know so they can discuss testing with their own doctors. This is the same logic behind cascade screening, long used for inherited cholesterol conditions: one diagnosis becomes a chance to protect a whole family.

Common Questions About Lp(a)